Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine

Intravacc and Celonic to develop and produce a novel COVID-19 vaccine • Combining Intravacc’s OMV-delivery platform with Covid-19 Spike proteins • Preclinical studies to start shortly for candidate selection and inhouse pilot scale GMP production

Strain selection and generation

  • For development and improvement of viral or bacterial based vaccines the scientists at Intravacc have extensive experience in structural and translational microbiology in order to design and create the best candidate organism for the candidate vaccine with the highest immunity, potency and production yield.
  • Viral vaccine design includes optimization of both the production cell line, as well as the virus strain for development of inactivated virus, live-attenuated virus, VLP, and alternatives like SRIP, replicons and virus-vectors.
  •  Bacterial vaccine design includes inactivated bacteria, toxins, conjugate vaccines, and vaccines against any pathogen using our OMV-platform
  • Antigen selection is performed via bioinformatics or forced evolution, in silico design and subsequent construction. Factors that are taken into account include: optimization of safety, immunogenicity (such as level of expression, epitope optimization), intrinsic antigen stability, intrinsic safe adjuvant (LPS), conservation of the antigen and vaccine yield.
  • To optimize GMP readiness bacterial strains are genetically modified without selection markers present in the final production strain and viral strains are rescued based on their genetic sequence, thereby circumventing the use of clinical isolates that might harbor extraneous viruses.

We have the following tools available:

  1. 1. Cloning, transfection, propagation
  2. 2. Transfection
  3. 3. Deep sequencing
  1. 4. siRNA screen
  2. 5. Crispr/Cas9
  3. 6. Viral vector design
  4. 7. Protein design